The global CMO CDMO market size was valued at USD 216.02 billion in 2025 and is projected to grow from USD 233.78 billion in 2026 to USD 439.81 billion by 2034, registering a CAGR of 8.22% during the forecast period (2026–2034). North America dominated the CMO CDMO market with a share of 33.20% in 2025.
CMO and CDMO services refer to outsourced pharmaceutical services that support drug development, manufacturing, and commercialization for pharmaceutical and biotechnology companies. CMO and CDMO services are commonly tracked under HSN Code 9983 (other professional, technical, and business services) and SIC Code 2834 (Pharmaceutical Preparations).
The CMO CDMO market demand is driven by outsourcing of drug development and manufacturing and a shift toward specialized production capabilities. Pharmaceutical and biotechnology companies are increasingly using API manufacturing, formulation development, clinical manufacturing, commercial manufacturing, and biologics production, contributing to the CMO CDMO market growth.
By Service
By Contract Manufacturing Service
By Molecule
By Small Molecules
By Large Molecules
By Advance Therapies
By End User
Download a Free Sample To learn more about this report,
Integration of Advanced Analytical Technologies with Contract Manufacturing
The CMO CDMO market analysis shows a shift toward the integration of advanced analytical technologies with contract manufacturing to improve drug development, process monitoring, quality testing, and product characterization. This integration is supporting greater quality control and improving efficiency across pharmaceutical manufacturing activities.
Development of End-to-End Pharmaceutical Development Services
The CMO CDMO market is witnessing greater development of end-to-end pharmaceutical development services that cover multiple stages from formulation development and analytical testing to clinical manufacturing and commercial production. This development is supporting streamlined workflows, reduced technology transfer requirements, and faster movement of drug candidates toward commercialization.
Supply chain disruptions are expected to have a high impact on the CMO CDMO market share due to dependence on active pharmaceutical ingredients (API), specialty chemicals, biopharmaceutical materials, single-use manufacturing components, packaging materials, and temperature-controlled logistics. The market is expected to follow a stair-step recovery, as shortages of pharmaceutical inputs, manufacturing delays, equipment constraints, and transportation disruptions can affect production schedules in phases before material availability and manufacturing capacity stabilize. The market is expected to grow at a CAGR of 8.22%, but supply chain constraints could approximately lower this by 1.0 percentage point, resulting in short-term growth of around 7.22%. As supply conditions normalize through improved availability of pharmaceutical inputs and manufacturing components, expanded production capacity, stable cold chain infrastructure, and smoother pharmaceutical logistics, CMO CDMO market growth is expected to gradually return to 8.22%.
The CMO CDMO market forecasts strategic investment activity driven by expansion of pharmaceutical manufacturing capacity, advanced biologics and injectable production, complex drug modalities, specialized CDMO capabilities, and increasing demand for outsourced drug development and manufacturing services.
Key Investment and Funding Activities in CMO CDMO Market, 2026
Resilience
USD 750 Million
In July 2026, Resilience and Eli Lilly expanded their strategic partnership with a USD 750 million investment to increase U.S. manufacturing capacity for injectable medicines in Ohio.
Aarti Pharmalabs
USD 48 Million
In 2026, Aarti Pharmalabs invested approximately USD 48 million in capital expenditure to expand its CMO and CDMO capabilities, including capacity expansion and production debottlenecking.
Demand for Flexible Manufacturing Capacity and Specialized Drug Development Capabilities Drives Market
The demand for flexible manufacturing capacity is growing as pharmaceutical companies need production facilities that can handle different drugs and batch sizes. Flexible facilities allow CMOs and CDMOs to adjust production based on changing client requirements. This helps companies manage capacity needs without investing heavily in their own facilities.
The demand for specialized drug development capabilities is increasing as pharmaceutical and biotech companies develop more complex therapies. CMOs and CDMOs provide expertise in formulation, process development, analytical testing, and other specialized activities. Access to these capabilities helps companies manage complex development programs and reduce internal resource needs.
Long Lead Times for Complex Manufacturing Projects and Stringent Regulatory Compliance Requirements Restrains Market Expansion
Long lead times for complex manufacturing projects can create challenges for pharmaceutical companies using CMO and CDMO services. Projects involving specialized formulations, biologics, sterile manufacturing, or complex technology transfers may require extensive development, validation, and production planning.
Stringent regulatory compliance requirements can increase the complexity and cost of CMO and CDMO operations. Service providers must maintain strict standards for manufacturing processes, quality control, documentation, validation, and facility operations across different markets. These requirements can increase operational burdens and restrain market expansion.
Expansion of CMO CDMO Services for Biologics Manufacturing and Clinical Trial Production Offers Growth Opportunities
The development of biologic drugs is creating opportunities for CMO and CDMO providers to serve pharmaceutical and biotechnology companies. Specialized facilities can support formulation, process development, and commercial manufacturing of complex biologics. Revenue can be generated through contract manufacturing, development services, and long-term production agreements, contributing to CMO CDMO market growth.
The increasing number of drug candidates entering clinical trials is creating opportunities for CMO and CDMO providers to support pharmaceutical companies with small batch and clinical manufacturing needs. Outsourced services can cover formulation, packaging, testing, and regulatory support.
The contract manufacturing services segment accounted for a share of 58.37% in 2025 due to increasing outsourcing of pharmaceutical manufacturing activities by drug developers.
The contract development services segment is expected to grow at a CAGR of 9.18% during the forecast period, driven by the demand for formulation development, analytical services, process optimization, and other development capabilities.
Request Customizationto receive a tailored report.
The commercial scale manufacturing segment is expected to grow at a CAGR of 7.58% during the forecast period, supported by the demand for large volume production of approved and commercially launched medicines.
The clinical scale manufacturing segment is expected to grow at a CAGR of 9.04% during the forecast period, driven by increasing number of drug candidates progressing through clinical development.
The small molecules segment accounted for a share of 52.64% in 2025 owing to the large number of conventional pharmaceutical products manufactured through established small molecule processes.
The advanced therapies segment is expected to grow at a CAGR of 14.38% during the forecast period, fueled by the development of cell-based, gene-based, and RNA-based therapies.
The generic drugs segment accounted for a share of 46.37% in 2025 due to the large global volume of off patent medicines and continued demand for cost effective drug manufacturing.
The high potency APIs segment is expected to grow at a CAGR of 9.74% during the forecast period, shaped by the development of medicines requiring specialized containment and handling capabilities.
The monoclonal antibodies segment accounted for a share of 35.72% in 2025 due to their extensive use across oncology, autoimmune disorders, and other therapeutic areas.
The biosimilars segment is expected to grow at a CAGR of 10.84% during the forecast period, supported by the development of biologic alternatives and demand for cost efficient manufacturing capabilities.
The cell therapy segment accounted for a share of 30.82% in 2025 due to increasing development of personalized and immune based cell therapies.
The RNA therapeutics segment is expected to grow at a CAGR of 15.94% during the forecast period, driven by increasing development of RNA-based medicines and expanding manufacturing requirements.
The pharmaceutical companies segment accounted for a share of 61.73% in 2025 owing to their extensive outsourcing of drug development and manufacturing activities.
The biotechnology companies segment is expected to grow at a CAGR of 9.74% during the forecast period, supported by increasing drug pipelines and limited internal manufacturing infrastructure among emerging biotechnology developers.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Supported by Pharmaceutical Outsourcing and Drug Manufacturing
The North America CMO CDMO market accounted for a the share of 33.20% in 2025.
The United States CMO CDMO market is supported by increasing demand for pharmaceutical outsourcing and specialized drug manufacturing. The U.S. Food and Drug Administration selected seven participants for its PreCheck Pilot Program to support expansion of domestic pharmaceutical manufacturing capacity and strengthen the U.S. drug supply chain. This development supports continued investment in domestic manufacturing infrastructure and outsourcing capabilities.
The Canada CMO CDMO market is shaped by booming pharmaceutical and biotechnology pipeline, increasing the need for external manufacturing capacity, particularly for specialized products and clinical development programs.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific: Fastest Growth Supported by Biopharmaceutical Manufacturing Expansion and Clinical Trial Manufacturing
The Asia Pacific CMO CDMO market is expected to grow at a CAGR of 10.48% during the forecast period, making it the fastest growing region.
The India CMO CDMO market is supported by the demand for biopharmaceutical manufacturing and outsourced drug production. India’s Biopharmaceutical Mission has supported the development of manufacturing capabilities for vaccines, biologics, and biosimilars. Resulting in strengthening the country’s capacity to supply clinical and commercial biopharmaceutical products.
The China CMO CDMO market is shaped by the demand for clinical trial manufacturing and biopharmaceutical production. China’s growing number of innovative biologic drug approvals and clinical stage programs is increasing demand for manufacturing capacity for clinical trial materials, particularly for monoclonal antibodies and other biologics.
The Japan CMO CDMO market benefits from the demand for biopharmaceutical manufacturing and specialized outsourcing services. Japan’s growing development of regenerative medicine and cell therapy products is creating demand for specialized manufacturing capabilities to support clinical development and commercial production.
Middle East & Africa: Market Growth Supported by Biologics Manufacturing
The Middle East & Africa CMO CDMO market is expected to grow at a CAGR of 8.67% during the forecast period.
The UAE CMO CDMO market is led by the by expansion of drug product manufacturing and local pharmaceutical production. The Emirates Drug Establishment showcased the Holistic National Manufacturing project, which aims to build a comprehensive domestic base for producing advanced medicines and strengthen pharmaceutical supply chains.
The South Africa CMO CDMO market is fueled by growing biologics manufacturing capabilities. The CSIR highlighted its FuturePHARMA Investigational Vaccines and Biologics Facility, which supports development and local manufacturing of vaccines, biologics, and other high value biological medicines.
Latin America: Market Expansion Led by Pharmaceutical Development and GMP Manufacturing
The Latin America CMO CDMO market is expected to grow at a CAGR of 8.31% during the forecast period. Brazil’s National Health Surveillance Agency (ANVISA) continues to strengthen requirements for pharmaceutical development and manufacturing quality, encouraging manufacturers and contract partners to adopt structured quality systems throughout drug production. The Federal Commission for the Protection against Sanitary Risk (COFEPRIS) applies good manufacturing practices (GMP) requirements to pharmaceutical manufacturing facilities, supporting demand for manufacturing partners with established quality and production capabilities.
Europe: Market Growth Driven by Expansion of Pharmaceutical Services and Biotechnology Outsourcing
The Europe CMO CDMO market is expected to grow at a CAGR of 7.64% during the forecast period.
The UK CMO CDMO market is driven by the demand for biotechnology outsourcing and pharmaceutical services. The UK’s Cell and Gene Therapy Catapult is expanding access to advanced therapy development and manufacturing capabilities, supporting biotechnology companies that require external expertise and production capacity during clinical development.
The Germany CMO CDMO market is driven by the demand for pharmaceutical services and biotechnology outsourcing. Germany’s BioNTech announced expansion of its clinical stage manufacturing capabilities, supporting the growing need for specialized production and development services for innovative biopharmaceutical products.
The CMO CDMO market competitive landscape is highly fragmented, with established contract manufacturing organizations (CMO), contract development and manufacturing organizations (CDMO), pharmaceutical manufacturing service providers, and specialized biopharmaceutical manufacturing companies. Key players such as Lonza, Catalent, Thermo Fisher Scientific, WuXi AppTec, and Wacker Chemie AG are estimated to account for approximately 25–30% of the global CMO CDMO market share.
Established players compete mainly through manufacturing capabilities, drug development services, production scalability, regulatory expertise, quality standards, and specialized pharmaceutical technologies. Emerging and regional players in the CMO CDMO market ecosystem focus on specialized manufacturing services, flexible production capacity, and application-specific pharmaceutical development and manufacturing solutions.
July 2026: Formycon and OneSource Specialty Pharma partnered to expand integrated biosimilar drug substance and drug product manufacturing capabilities.
June 2026: Aurobindo Pharma inaugurated a biologics contract manufacturing facility in Telangana to expand bioreactor production and aseptic fill and finish capabilities.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Experts
The Straits Research Team is a group of experienced researchers, analysts, and industry professionals dedicated to delivering reliable, insightful, and well-structured market intelligence. With expertise across multiple sectors and domains, the team combines extensive research, data analysis, and industry knowledge to provide a clear understanding of evolving markets and business environments.
The team focuses on identifying key market trends, emerging opportunities, technological developments, competitive landscapes, and changing industry dynamics. Through a thoughtful and research-driven approach, it aims to provide valuable insights that help businesses, investors, and decision-makers better understand their industries and make informed strategic decisions.
Leukemia Therapeutics Market Size, Share, Growth, Demand, Analysis, 2034
Acetaminophen Market Size, Share, Growth, Analysis, 2034
Docetaxel Market Size, Share, Growth, Analysis, Report, 2034
Phenylketonuria Market Size, Share, Growth, Analysis, Report, 2034
Ovarian Cancer Market Size, Share, Growth, Analysis, Report, 2034
Tulathromycin Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com